Related Experiment Video
Updated: Mar 28, 2026

Chronic Post-Ischemia Pain Model for Complex Regional Pain Syndrome Type-I in Rats
Published on: January 21, 2020
SIRPα1-SHP2 Interaction Regulates Complete Freund Adjuvant-Induced Inflammatory Pain via Src-Dependent GluN2B
Cheng-Yuan Lai1, Tzer-Bin Lin, Ming-Chun Hsieh
1From the Department of Medicine, Mackay Medical College, New Taipei, Taiwan; Department of Veterinary Medicine, College of Veterinary Medicine, National Chung-Hsing University, Taichung, Taiwan; Department of Biotechnology, Asia University, Taichung, Taiwan; Graduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan; Department of Physiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Department of Physiology, School of Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan; and Department of Obstetrics and Gynecology, Chung-Shan Medical University Hospital, Chung-Shan Medical University, Taichung, Taiwan.
Background:
The elusiveness of pain mechanisms is a major impediment in developing effective clinical treatments. We examined whether the signal regulatory protein α1 (SIRPα1)-activated spinal Src homology-2 domain-containing protein tyrosine phosphatase 2 (SHP2)/Src cascade and the downstream GluN2B phosphorylation play a role in inflammatory pain.
Methods:
At hour 3 and days 1, 3, 5, and 10 after the intraplantar injection of complete Freund adjuvant (CFA), we assessed paw withdrawal latency using the Hargreaves test and analyzed dorsal horn samples (L4-L5) by Western blotting and immunoprecipitation.
Results:
Intraplantar CFA injection provoked the behavioral hyperalgesia in the ipsilateral hind-paw along with SIRPα1, phosphorylated SHP2 (pSHP2), phosphorylated Src (pSrc), and phosphorylated GluN2B expressions and total SHP2 (tSHP2)-SIRPα1/pSHP2/pSrc and total Src (tSrc)-SIRPα1/pSHP2/pSrc coprecipitation in the ipsilateral dorsal horn. Although both of them failed to show an effect on CFA-enhanced SIRPα1 expression, spinal administration with SIRPα1-neutralizing antibody (10, 50, and 100 μg, 10 μL) and 8-Hydroxy-7-[(6-sulfo-2-naphthyl)azo]-5-quinolinesulfonic acid (NSC 8787; an SHP2 antagonist, 1, 10, and 100 μM, 10 μL) dose-dependently attenuated the behavioral hyperalgesia, SHP2 and Src phosphorylation, and tSHP2-SIRPα1/pSHP2/pSrc coprecipitation at day 1 after CFA injection. Intrathecal application of 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2; a Src-family kinase inhibitor, 10, 30, and 50 nM, 10 μL) exhibited a similar effect as these agents, except that it failed to ameliorate CFA-enhanced SHP2 phosphorylation and tSHP2-SIRPα1/pSHP2 coprecipitation.
Conclusions:
CFA-induced spinal SIRPα1 expression, which triggers SHP2, and Src phosphorylation, which subsequently induced pSrc-GluN2B interaction to mediate the GluN2B activation, contribute to spinal plasticity underlying the maintenance of inflammatory pain. These findings provide a possible strategy for pain relief by targeting to spinal SIRPα1-SHP2 coupling.
Insights
The signal regulatory protein alpha1 (SIRPα1)-activated spinal SHP2/Src cascade and GluN2B phosphorylation are key mediators of inflammatory pain. Targeting this SIRPα1-SHP2 pathway offers a potential strategy for pain relief.
Area of Science:
- Neuroscience
- Pain Research
- Molecular Biology
Background:
- Understanding pain mechanisms is crucial for developing effective treatments.
- The role of the SIRPα1-activated spinal SHP2/Src cascade and GluN2B phosphorylation in inflammatory pain remains unclear.
Purpose of the Study:
- To investigate the involvement of the SIRPα1-activated spinal SHP2/Src cascade and downstream GluN2B phosphorylation in inflammatory pain.
- To explore potential therapeutic targets for inflammatory pain management.
Main Methods:
- Complete Freund's adjuvant (CFA) induced inflammatory pain model in rodents.
- Assessment of paw withdrawal latency using the Hargreaves test.
- Western blotting and immunoprecipitation analysis of dorsal horn (L4-L5) samples.
Main Results:
- CFA injection induced hyperalgesia and increased expression of SIRPα1, pSHP2, pSrc, and pGluN2B.
- SIRPα1-neutralizing antibody and SHP2 antagonist (NSC 8787) dose-dependently attenuated hyperalgesia and related signaling.
- Src inhibitor (PP2) reduced hyperalgesia but did not affect SHP2 phosphorylation or associated signaling.
Conclusions:
- CFA-induced spinal SIRPα1 expression triggers SHP2 and Src phosphorylation, leading to pSrc-GluN2B interaction and activation, contributing to inflammatory pain.
- Targeting spinal SIRPα1-SHP2 coupling presents a promising strategy for inflammatory pain relief.
Related Concept Videos
The JAK-STAT Signaling Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
GPCRs Regulate Adenylyl Cylase Activity

